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tAbstract
In our functional dissection of the CD33 Alzheimer’s disease susceptibility locus, we find that the
rs3865444C risk allele is associated with greater cell surface expression of CD33 in monocytes
(t50 = 10.06, pjoint=1.3×10–13) of young and older individuals. It is also associated with (1)
diminished internalization of Aβ 42) (2) accumulation of neuritic amyloid pathology and fibrillar
amyloid on in vivo imaging and (3), increased numbers of activated human microglia.
Recent genome-wide studies have identified nine AD susceptibility loci, including CD33
and MS4A4/MS4A6E, which implicate the immune system in AD susceptibility1–7.
Currently, the most strongly associated marker in the CD33 locus is rs38654445, and higher
CD33 expression levels in the brain have been associated with more advanced cognitive
decline and AD.8, 9 CD33, also known as Siglec-3, is a 67-KDa transmembrane glycoprotein
expressed on the surface of myeloid progenitor cells, mature monocytes and macrophages. It
functions as a lectin, a carbohydrate-binding protein, and it contains putative
immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that are typically inhibitors of
cellular activity. In support of this putative function, CD33 has been shown to constitutively
repress monocyte-derived pro-inflammatory cytokines10.
To explore the functional consequences of the CD33 locus, we accessed genotyped,
archived samples from the Brigham and Women’s Hospital PhenoGenetic Project
(Supplemental Table 1a). In these 32 young subjects, we found a seven-fold increase in
CD33 cell surface expression of circulating monocytes in relation to the rs3865444C risk
allele (t31 = 8.48, p=1.4×10−9), but the frequency of CD33+ monocytes does not vary in
relation to rs3865444 (Supplemental Fig. 1). rs3865444C explains 72.8% of the variance in
CD33 cell surface expression level. We replicated this result in an independent set of 19
young subjects from the PhenoGenetic Project (t18 = 6.29, p=6.3×10−6), and a joint analysis
of both sets of subjects is highly significant (t50 = 10.06, pjoint=1.3×10−13) (Fig. 1a). Given
that AD manifests primarily in older age and that immune system function changes
significantly with age, we performed an additional replication analysis using 175 older
subjects, both with and without a diagnosis of AD, from three prospective cohort studies of
aging: the Memory and Aging Project (MAP) (n=60)11, the Religious Orders Study (ROS)12
(n=91), and the Chicago Health and Aging Project (CHAP) (n=24)13 (Supplementary Table
1b). We once again replicated the association of higher CD33 expression with rs3865444C
(z = 10.13, p=.4.1 × 10−24), after adjusting for age, sex and batch effect (Fig. 1b); here,
rs3865444C explained 70.4% of the variance in CD33 cell surface expression. We found no
significant interaction by AD diagnosis in the ROS/MAP subjects (z = −0.80, p=0.43) in
whom this phenotype is available. Thus, the relation of genotype and CD33 expression
appears to hold throughout the life course, and the effect of this susceptibility allele may
therefore play a role in the earliest stages of AD. In our data, we do not find an effect of age
on CD33 surface expression.
Since myeloid cells such as infiltrating macrophages or microglia are thought to play a role
in AD by phagocytosis of amyloid β  that accumulates in neuritic amyloid plaques (a key
neuropathologic feature of AD14), we tested the hypothesis that monocytes from subjects
with the rs3865444C CD33 risk allele have a reduced state of activation and therefore
reduced phagocytic ability compared to subjects with the protective allele. We find that
circulating monocytes bearing the rs3865444C risk allele demonstrate reduced uptake of
both fluorescently-labeled dextran (t29 = 3.33, p=0.003) (Fig. 1c) and amyloid Aβ  (Aβ  (42))
(t31 = 3.64, p=0.001)(Fig. 1d). We replicated this observation in an independent set of
subjects (t128 = 2.18, p= 0.03)(Supplementary Fig. 2). These results suggest that the
alteration in uptake may be relevant to the context of AD pathology where amyloid toxicity
caused by the fibrillogenic Aβ (42) form of amyloid plays an important role. Interestingly,
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twe observed that, while the effect of rs3865444C is additive for CD33 expression, it may be
dominant for functional traits (such as substrate uptake) (Supplementary Table 2).
To investigate whether these functional consequences of the CD33 risk allele could lead to
alterations of amyloid biology associated with AD, we examined two collections of older
subjects (Supplementary Table 3a) that have undergone positron emission tomography
imaging with Pittsburgh Compound B (PiB), which measures an individual’s burden of
pathogenic fibrillar amyloid. Subjects are categorized into PiB positive (PiB+) and negative
subsets (Fig. 2a,b), and the PiB+ subset is more likely to develop cognitive impairment and
AD15. In a joint analysis of the two collections (n=218 total), we find that the rs3865444C
risk allele is associated with a greater likelihood of being PiB+ (Fig. 2c,d), and as with the
internalization phenotype, the effect of rs3865444C appears to fit a dominant model (χ 2(1) =
5.52, p=0.02) better than an additive model (χ 2(1) = 2.78, p=0.1). The association holds if
we use the PiB burden as a quantitative trait (dominant model z = 2.35, p=0.02) in
secondary analyses. Importantly, the magnitude and direction of the association linking
rs3865444C with being PiB+ remains when the analysis is limited to asymptomatic older
subjects, however the results are no longer significant, possibly because of the reduced
sample size (Supplementary Table 3b). Overall, these data support a role for the rs3865444C
susceptibility allele in in vivo amyloid accumulation in the presymptomatic phase of AD.
Next, we assessed the role of rs3865444C in the accumulation of neuritic amyloid plaques
measured at autopsy. In ROS/MAP subjects, we see that rs3865444C is also associated with
greater neuritic amyloid plaque burden (z = 2.47, p=0.01). Further, we found that
rs3865444C is associated with a greater likelihood of a pathologic diagnosis of AD (χ 2(1) =
6.54, p=0.01). rs3865444C is not associated with the burden of neurofibrillary tangles (z =
1.40, p=0.16) (Supplementary Table 4). Given that these analyses were performed in
individuals with measurements of CD33 expression in peripheral monocytes frozen prior to
death, we assessed whether the level of CD33 expression in monocytes mediated some of
the effect of the risk allele on neuropathologic traits. We found that the effect size of the
relation of rs3865444C to neuritic amyloid plaque burden is diminished by 10% and is no
longer significant (z = 1.74, p=0.08) when we add a covariate for the level of CD33
expression to the model. Thus, these two prospectively collected autopsy cohorts support a
role for monocytes in statistically mediating some of the functional consequences of the
CD33 risk allele that ultimately result in the accumulation of amyloid pathology and AD.
To further explore the possible role of CD33 in the brain of older subjects, we examined
tissue sections from MAP subjects and report that CD33 is expressed in cells that have the
morphologic attributes of microglia/macrophages (Fig. 3a–c). The CD33-expressing cells
are found in the vicinity of neuritic plaques (Fig. 3a).
In older age, activated myeloid cells such as those that express CD33 are seen in the brain of
cognitively non-impaired and demented individuals16. In ROS/MAP subjects, we find that
the mean proportion of terminally activated microglia/macrophage (stage III microglia or
macrophage) is significantly elevated relative to the rs3865444C risk allele (z = 3.06,
p=0.003) in the inferior temporal lobe (which is an early target of AD-related amyloid
neuropathology) (Fig. 3d), and there is a suggestion that it is elevated in the posterior
putamen region (z = 2.42, p=0.017), after accounting for the testing of four hypotheses (Fig.
3e) (Supplemental Table 5a). These associations remain after adjusting for a diagnosis of
AD (Supplemental Table 5b). This observation is consistent with a model for the AD
association in which monocytes from subjects with the risk allele are less able to uptake
Aβ (42), which could lead to an accumulation of activated but less functional microglia/
macrophages in the brain, where they fail to clear amyloid β  plaques.
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tWe have begun to characterize the functional consequences of the CD33 AD susceptibility
locus in early and late-life. These results are consistent with a recent report that decreasing
CD33 expression in mice leads to enhanced Aβ (42) uptake by macrophage/microglia and
decreased accumulation of brain amyloid in a mouse model.9 CD33 is thought to be an
inhibitory lectin, and thus increased cell surface expression of CD33 due to the risk allele
could lead to down-regulation of myeloid cell activity, such as the reduced uptake of
Aβ (42). Such alterations of myeloid function throughout life could lead to the earlier
accumulation of fibrillar amyloid as measured by PiB imaging in older brains, and,
ultimately, the accumulation of more neuritic amyloid pathology and a greater likelihood of
meeting a diagnosis of AD on neuropathologic examination.
The observation that the functional consequences of this variant are seen in younger and
presymptomatic older subjects brings up the possibility that the CD33 risk allele and altered
CD33 function could have a role in the very early presymptomatic phase of AD, in middle
or younger age. Further, our data from young subjects with the risk allele suggest that AD-
associated alterations in immune function that have previously been reported are not solely a
feature of immune senescence in older age or a late reaction to the toxicity of amyloid and
other AD-related pathologies. It is not yet clear how CD33-related dysfunction of innate
immune cells relates to all manifestations of AD: it seems to contribute to known
neuropathologic features of AD such as the accumulation of amyloid pathology but may
well also be involved in inflammatory events that are associated with AD and remain to be
further characterized.
The data reported here integrate well with an existing literature exploring the role of innate
immune system dysfunction in AD14 and, critically, identifies a specific molecule, CD33,
that links genetic susceptibility, altered myeloid function, and amyloid pathology to an early
role in the pathogenesis of AD. These data therefore present (1) an intriguing novel target
with which to manipulate amyloid pathology and (2) pertinent information that could be
leveraged in algorithms with which to identify individuals at high risk of accumulating
amyloid who are being targeted in clinical trials of presymptomatic AD.17, 18 More
proximally, CD33 and its alteration of myeloid function may influence responses to the
antibody-mediated therapeutic approaches that are currently being tested in AD19,20.
Online methods
Study Subjects
Informed consent was obtained on all human subjects. All blood draws, brain autopsies,
experiments and data analysis were done in compliance with protocols approved by the
Institutional Review Board of each Institution.
The Brigham & Women’s Hospital (BWH) PhenoGenetic Project—Peripheral
venous blood was obtained from healthy control volunteers in compliance with protocols
approved by the Institutional Review Board of Partners Healthcare. The PhenoGenetic
Project is a living tissue bank that consists of healthy subjects that are re-contactable based
on their genotype. 1741 healthy subjects >18 years old have been recruited from the general
population of Boston, MA. They are free of chronic inflammatory, infectious and metabolic
diseases. Their median age is 24, and 62.7% of subjects are women. For the CD33
expression experiments the median age was 26.5 (range=20.0–50.0). All of the
PhenoGenetic subjects used in the uptake assay using dextran, and 25 of the subjects used in
the Aβ (42) uptake assay were also used in the CD33 staining assay. 67% the subjects used in
the Aβ (42) uptake assay were also used in the dextran uptake assay.
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tThe Rush Religious Orders (ROS) Study and Memory and Aging Project
(MAP), and Chicago Health and Aging Project—Study participants were free of
known dementia at enrollment, agreed to annual clinical evaluations, and signed an
Anatomic Gift Act donating their brains at death. ROS, started in 1994, enrolls Catholic
priests, nuns and brothers, aged 53 or older from about 40 groups in 12 states. Since January
1994, more than 1,150 participants completed their baseline evaluation, of whom 87% are
non-Hispanic white, and the follow-up rate of survivors and autopsy rate among the
deceased both exceed 90%. MAP, started in 1997, enrolls men and women aged 55 or older
and with no evidence of dementia at baseline from assisted living facilities in the Chicago
area in compliance with protocols approved by the Institutional Review Board of RUSH
University. Since October 1997, more than 1,550 participants completed their baseline
evaluation, of which 87% were non-Hispanic white. The follow-up rate of survivors exceeds
90% and the autopsy rate exceeds 80%. More detailed descriptions of ROS, MAP and
CHAP can be found in prior publications11, 12. The median age of subjects used in the CD33
expression experiments at sampling was 79.9, (range=65.8–94.8).
The Harvard Aging Brain Study—The Harvard Aging Brain Study is a longitudinal
study of older individuals between the ages of 65 and 85 years old. Participants were
evaluated with an extensive battery of functional and neuropsychological tests. All
participants had a Clinical Dementia Rating of 021, performed no worse than 1.5 SD units
below the age- and education-corrected norm on the Logical Memory IIa subtest of the
Wechsler Memory Scale-Revised22, and scored 26 or above on the Mini-Mental State
Examination23. Participants were excluded if previously diagnosed with a neurological or
psychiatric condition or if they scored >11 on the Geriatric Depression Scale24. Participants
provided informed consent in accordance with protocols approved by the Partners
Healthcare Inc. Institutional Review Board.
The Alzheimer’s Disease Neuroimaging Initiative—The Alzheimer’s Disease
Neuroimaging Initiative (ADNI) is a large multicenter, longitudinal, observational trial
taking place across North America, in which subjects with normal cognition, amnestic MCI,
and mild AD are followed up with periodic neuropsychological testing, multiple imaging
techniques, and fluid biomarkers (www.loni.ucla.edu\ADNI). ADNI is a result of the efforts
of many co-investigators from a broad range of academic institutions and private
corporations, and subjects have been recruited from over 50 sites across the United States
and Canada. Subjects (N= 96) with complete baseline clinical datasets were included in the
current analysis. They were aged 55 to 89 years, in general good health or had stable
medical problems at the time of screening, and had a study partner/caregiver able to provide
an independent evaluation of the subject’s cognitive, behavioral, and functional status.
Subjects did not have significant neurological conditions, significant active psychiatric
disorders, or alcohol or substance abuse within 2 years of screening. All subjects underwent
comprehensive neuropsychological testing (assessing memory, attention, executive function,
language, and visuospatial function) and additional study partner questionnaires about
behavior and daily functioning. All subjects had a global Clinical Dementia Rating scale21
(CDR) score = 0, 0.5 or 1.
Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu). The ADNI was launched in
2003 by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging
and Bioengineering (NIBIB), the Food and Drug Administration (FDA), private
pharmaceutical companies and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to test whether serial magnetic
resonance imaging (MRI), positron emission tomography (PET), other biological markers,
and clinical and neuropsychological assessment can be combined to measure the progression
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tof mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Determination of
sensitive and specific markers of very early AD progression is intended to aid researchers
and clinicians to develop new treatments and monitor their effectiveness, as well as lessen
the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center
and University of California – San Francisco. ADNI is the result of efforts of many co-
investigators from a broad range of academic institutions and private corporations, and
subjects have been recruited from over 50 sites across the U.S. and Canada. The initial goal
of ADNI was to recruit 800 subjects but ADNI has been followed by ADNI-GO and
ADNI-2. To date these three protocols have recruited over 1500 adults, ages 55 to 90, to
participate in the research, consisting of cognitively normal older individuals, people with
early or late MCI, and people with early AD. The follow up duration of each group is
specified in the protocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects originally recruited
for ADNI-1 and ADNI-GO had the option to be followed in ADNI-2. For up-to-date
information, see www.adni-info.org.
Genotypes
Subjects from the BWH PhenoGenetic Project and HAB were genotyped using DNA
isolated from whole blood and the iPLEX™ Sequenom MassARRAY platform (genotype
call rate > 95%, Hardy-Weinberg Equilibrium P value >0.001).
In the ROS, MAP, CHAP and ADNI subjects, imputed dosage values were used for analyses
of the rs3865444C allele. In all four cohorts, DNA was extracted from whole blood or frozen
post-mortem brain tissue. Genotype data was generated using the Affymetrix Genechip 6.0
platform at the Broad Institute’s Genetic Analysis Platform or the Translational Genomics
Research Institute. Both sets of data underwent the same quality control (QC) analyses in
parallel using the PLINK toolkit (http://pngu.mgh.harvard.edu/~purcell/plink/) and quality
controlled genotypes were pooled. The QC process included a principal components
analysis using default parameters in EIGENSTRAT25 to identify and remove population
outliers. Imputation in ROS and MAP was performed using MACH software (version
1.0.16a) and HapMap release 22 CEU (build 36). The imputation quality score (INFO) for
rs3865444 is 0.9963, suggesting that the SNP is imputed with a high level of confidence.
Cells and Flow Cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Paque PLUS (GE
Healthcare, Piscataway, NJ) gradient centrifugation. PBMCs were frozen at a concentration
of 1–3×107 cells/ml in 10% DMSO (Sigma-Aldrich, St. Louis, MO)/90% FCS (Atlanta
Biologicals, Lawrenceville, GA). After thawing, PBMCs were washed in 10 ml PBS.
PBMCs were stained with anti-human CD33 (clone AC104.3E3; Miltenyi, Auburn, CA) or
mouse IgG1 isotype (Miltenyi) in PBS plus 1% FCS. The monocyte gate was defined based
on their distinct forward and side-scatter profile. The MFI was acquired on a FACSCalibur
(BD Immunocytometry Systems, San Jose,CA) and analyzed with FlowJo software (Tree
Star, Ashland, OR). An additive model was used in the analysis, adjusting for age and sex.
Given the availability of genotyped samples in the phenogenetic cohort, the AA and CC
genotype classes were over-sampled in figure 1a, while the subjects used in figure 1b were
not selected by genotype and represent a random sample of subjects from the CHAP, MAP,
and ROS cohorts, which are prospective cohorts of initially non-demented individuals.
Uptake assays
We tested monocyte uptake ability in circulating monocytes using two different substrates
that have been deployed previously in this experimental paradigm26. After thawing, PBMCs
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twere washed in 10 ml PBS. Either 100,000 PBMCs/well or 50,000/well purified monocytes
were incubated with either 1 mg/ml FITC-labeled dextran (Sigma-Aldrich, Saint Louis, MO)
or 15 ng/ml HiLyte Fluor 488-labeled Aβ (42) (AnaSpec, San Jose, CA) in 96 well
polypropylene plates in HL-1 media plus 5% human serum for 1 hour at 37 °C or 4 °C. Cells
were then washed 3 times with PBS and fixed in 4% PFA for 30 minutes. The monocyte
gate was defined based on their distinct forward and side-scatter profile. The MFI was
acquired on a FACSCalibur (BD Immunocytometry Systems, San Jose, CA) and analyzed
with FlowJo software (Tree Star, Ashland, OR). Data shown is the change in MFI (delta
MFI) between samples incubated at 4 °C (where uptake is blocked) and 37 °C (where uptake
occurs). A dominant model was used in the analysis, adjusting for age and sex.
Pathology, Immunohistochemistry and Microglia quantification
Brains were removed in a standard fashion as previously described27–29. After weighing,
each brain was cut into 1cm coronal slabs using a Plexiglas jig. Slabs from one hemisphere,
and slabs from the other hemisphere not designated for rapid freezing, were fixed for at least
3 days in 4% paraformaldehyde. We used defined landmarks to obtain at least 2 tissue
blocks from each of the following regions: dorsolateral prefrontal cortex, middle and inferior
temporal cortex, inferior parietal, hippocampus CA1/subiculum, entorhinal cortex proper,
ventromedial caudate, and posterior putamen. Tissue blocks were processed, embedded in
paraffin, cut into either 6 micron or 20μ m sections, and mounted on glass slides.
Neuropathologic diagnoses were made by a board-certified neuropathologist blinded to age
and clinical data. Bielschowsky silver stain 6 micron sections were used to visualize neuritic
plaques, diffuse plaques, and neurofibrillary tangles in the frontal, temporal, parietal,
entorhinal, and hippocampal cortices, as previously described, for the pathologic diagnosis
of AD29. A neuropathologic diagnosis of “no AD,” “low likelihood AD,” “intermediate
likelihood AD,” or “high likelihood AD” was given based on semiquantitative estimates of
neuritic plaque density as recommended by CERAD and the neurofibrillary tangle stage by
Braak and Braak as recommended by the National Institute on Aging (NIA) - Reagan
criteria30. For analyses, the neuropathologic diagnosis of AD was considered absent if NIA-
Reagan diagnosis was no or low and present if intermediate or high likelihood29. The
density of neuritic plaques, diffuse plaques and neurofibrillary tangles was characterized
using Bielschowsky silver stain for visualization and a graticule to count total number of
each in a 1-mm2 area (100 magnification) of highest density. Counts for each marker were
completed for each of five regions (midfrontal cortex, middle temporal cortex, inferior
parietal cortex, entorhinal cortex, and hippocampus CA1/subiculum) and then converted to
standardized scores using the mean of the entire deceased cohort for that region29.
Immunohistochemistry for microglia was performed using an Automated Leica Bond
immunostainer (Leica Microsystems Inc., Bannockborn IL) and anti-human HLA-DP, DQ,
DR antibodies (clone CR3/43; DakoCytomation, Carpinteria CA; 1:100) using standard
Bond epitope retrieval and detection. An investigator blinded to the clinical and pathologic
data, outlined the cortical or subcortical gray region of interest on each slide using a
Microbrightfield Stereology System. The Stereo Investigator 8.0 software program was used
to place a 1000 × 750 μ m sampling grid over the region and the program was engaged to
sample 4.0% of the region with a 200 × 150 μ m counting frame at 400x magnification at
interval grid intersection points. Using separate tags for stage 1, 2 and 3 microglia, the
operator marked the microglia at each intersection point. These counts were then
upweighted by the stereology software to estimate total number of microglia (stage 1, 2 and
3) in the defined area. Different stages of activation from least (stage 1) to most (stage 3)
activated can be defined morphologically; when these cells become activated, their long fine
processes contract and thicken and the cell body adopts a larger more rounded cellular
conformation. Data from the two adjacent blocks of tissue (0.5 to 1.0 cm apart) were
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taveraged to obtain composite average densities of microglia in each region. For CD33
staining, an anti-human CD33 monoclonal antibody (clone PWS44; Leica Biosystems,
Germany) was used with diaminobenzidene (DAB) as chromagen. The amyloid deposits
were stained with the 10D5 antibody (courtesy of Elan pharmaceuticals) using alkaline
phosphatase as the chromagen.
PiB imaging
Amyloid burden was measured with N-methyl-[11C]-2-(4-methylaminophenyl)-6-
hydroxybenzothiazole (Pittsburgh Compound B; PiB), which binds to fibrillar amyloid, and
was prepared at Massachusetts General Hospital as described previously31, 32. Participants
underwent PiB PET imaging as described previously33, 34. Briefly, data were acquired using
a Siemens/CTI ECAT HR scanner (3D mode; 63 image planes; 15.2 cm axial field of view;
5.6 mm transaxial resolution and 2.4 mm slice interval; 39 frames: 8×15s, 4×60s, 27×120s).
After a transmission scan, 8.5 to 15mCi [11C]-PiB was injected as a bolus and followed
immediately by a 60 min dynamic acquisition. PET data were reconstructed and attenuation
corrected, and each frame was evaluated to verify adequate count statistics and absence of
head motion (interframe head motion, if present, was corrected before further processing).
The dynamic PET data were reconstructed with scatter correction using commercially
available routines for 3D PET data. PET data were parameterized by the distribution volume
ratio (DVR) computed using the Logan graphical analysis technique35 applied to the frame
data acquired 40 – 60 min after injection; this method has been fully validated for PiB
imaging36. Time-activity curves were measured in each brain region under analysis (region
of interest) and in a reference region in cerebellar cortex known to contain low levels of
fibrillar amyloid. This approach has been applied to numerous PiB studies36–39 and yields
data that are similar to arterial blood input methods37.
For each subject an index of PiB binding in cortical regions was calculated using the
dynamic data via Logan graphical modeling within a large aggregate cortical region of
interest consisting of frontal, lateral parietal and temporal, and retrosplenial cortices (the
FLR region). PiB retention in the FLR region is substantial in patients with diagnosed AD
and has been used as a summary measure of PiB retention in previous studies33, 34, 39. 1.25
is the value used to separate PiB+ and PiB− in the HAB cohort, and 1.5 is used to delineate
between PiB+ and PiB− in the ADNI cohort.
Statistical analysis
Demographic information on all datasets was presented using counts and percentages for
categorical variables and means and standard deviations or medians and ranges (minimum-
maximum) for continuous variables. The rs3865444 single nucleotide polymorphism (SNP)
was coded additively relative to the C allele in all analyses. Outcomes of interest were
assessed for normality and a square root or natural log transformation was performed if
necessary. For analysis of functional assays with small sample size all used Wilcoxon rank
sum tests. The associations between rs3865444C and our outcomes of interest were assessed
using linear regression models adjusted for experimental batch and study group where
appropriate. We evaluated the impact of outliers and possible confounding variables (e.g.
age, gender, education level), and adjusted for these variables in our statistical models if
they changed the effect estimate associated with the predictor by >10%. In addition to
include a covariate for experimental batch in our models where appropriate, to correct for
potential batch effects we have also applied an Empirical Bayes priors distribution
estimation framework (Combat v. 2.0)40, as implemented in Gene Pattern41 using a
parametric method. To correct for multiple comparisons, we performed a standard
Bonferroni correction by setting the threshold of significance equal to 0.05 divided by the
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tnumber of tests performed under each a priori hypothesis. Statistical analyses were
performed using SAS software, version 9.3 (SAS Institute, Cary, NC), the PLINK toolkit
(http://pngu.mgh.harvard.edu/~purcell/plink/) and R, version 2.13 (www.r-project.org).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. The CD33 risk allele is associated with increased CD33 expression and decreased
uptake
The MFI of CD33 protein expression on circulating monocytes of young healthy adults is
increased with the rs3865444C risk allele (a). There is a sevenfold increase in CD33
expression in rs3865444CC vs. rs3865444AA subjects. Monocytes from older adults also
have differential CD33 expression based on genotype (b). The MFI of FITC-labeled dextran
(c) and Aβ (42) (d) uptake by monocytes from young healthy adults is decreased with the
rs3865444C risk allele. Data shown is the change in MFI between samples incubated at 4°C
and 37°C. Each circle represents an individual. The mean of the distribution is denoted by a
horizontal line.
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tFigure 2. The susceptiblity allele of rs3865444 is associated with an increase in Pittsburgh
Compound B (PiB) imaging
PiB-PET images from a PiB− rs3865444AA subject (a) and a PiB+ rs3865444CC subject (b)
demonstrating a typical pattern of binding of PiB to amyloid plaque in the PiB positive
(DVR > 2.0) subjects and lack of binding (DVR ~= 1.0) in the PiB negative subjects. The
PiB values from the HAB (c) and ADNI (d) cohorts demonstrate an increased frequency of
PiB+ subjects with the rs3865444C risk allele. PiB+ and PiB− values are separated by a
dotted line.
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tFigure 3. Immunohistochemistry reveals CD33 expression in the brain and an increase
frequency of stage III microglia/macrophages associated with rs3865444C
(a) CD33+ microglia/macrophages (brown) are seen in sections of the dorsolateral prefrontal
cortex from a subject with pathologically confirmed AD; they are found in the vicinity of
amyloid deposits (red). (b) Adjacent sections labeled with anti-CR3/43 (top panel), a marker
for microglia/macrophage, and anti-CD33 (bottom panel) demonstrate that the cells staining
with anti-CD33 have the morphologic attributes of microglia/macrophage. (c) CD33 is
expressed at all 3 stages of activation in microglia/macrophages in the brain. The density of
stage 3 CR3/43+ microglia is increased in the inferior temporal region (d) and posterior
putamen region (e) with the rs3865444C risk allele. Each circle represents a subject. The line
represents the mean.
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